NCT02123654 - UNITY 3: A Japanese Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 in Subjects With Genotype 1 Chronic Hepatitis C | Biotech Hunter

Enrollment

297

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

January 31, 2015

Study Completion Date

August 31, 2015

Conditions

Hepatitis C Virus Infection

Interventions

DRUG

Daclatasvir

DRUG

Asunaprevir

DRUG

DCV 3DAA

OTHER

Placebo for DCV 3DAA

OTHER

Placebo for Daclatasvir

OTHER

Placebo for Asunaprevir

Trial Locations (35)

1058470

Local Institution, Minato-ku

1138655

Local Institution, Bunkyo-ku

1608582

Local Institution, Shinjuku-Ku

1808610

Local Institution, Musashino-shi

2138587

Local Institution, Kawasaki-shi

2320024

Local Institution, Yokohama

3500495

Local Institution, Iruma-gun

3700829

Local Institution, Takasaki

4093898

Local Institution, Chuo-shi

4678602

Local Institution, Nagoya

5008513

Local Institution, Gifu

5038502

Local Institution, Ogaki-shi

5438555

Local Institution, Osaka

5458586

Local Institution, Osaka

5640013

Local Institution, Suita

5650871

Local Institution, Suita-shi

6028566

Local Institution, Kyoto

6348522

Local Institution, Kashihara

6500047

Local Institution, Kobe

6638501

Local Institution, Nishinomiya-shi

7008558

Local Institution, Okayama

7348551

Local Institution, Hiroshima

7608557

Local Institution, Takamatsu

8108563

Local Institution, Fukuoka

8300011

Local Institution, Kurume-shi

8408571

Local Institution, Saga

8628655

Local Institution, Kumamoto

8800003

Local Institution, Miyazaki

8908520

Local Institution, Kagoshima

9188503

Local Institution, Fukui-shi

9208641

Local Institution, Kanazawa

9909585

Local Institution, Yamagata

466-8560

Local Institution, Nagoya

0600033

Local Institution, Sapporo

0608648

Local Institution, Sapporo